Does the media prefer AXGN or MMED?

In the previous week, MiniMed Group had 2 more articles in the media than AxoGen. MarketBeat recorded 4 mentions for MiniMed Group and 2 mentions for AxoGen. MiniMed Group's average media sentiment score of 0.51 beat AxoGen's score of 0.39 indicating that MiniMed Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiniMed Group 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, AXGN or TFX?

AxoGen has higher earnings, but lower revenue than Teleflex. AxoGen is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.81 -$15.70M -$0.68 N/A Teleflex $1.99B 2.67 -$905.64M -$23.29 N/A

Is AXGN or TFX more profitable?

AxoGen has a net margin of -13.36% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Teleflex -39.67% 11.93% 5.44%

Does the media refer more to AXGN or TFX?

In the previous week, Teleflex had 1 more articles in the media than AxoGen. MarketBeat recorded 3 mentions for Teleflex and 2 mentions for AxoGen. Teleflex's average media sentiment score of 1.15 beat AxoGen's score of 0.39 indicating that Teleflex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Teleflex 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, AXGN or HAE?

Haemonetics has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.81 -$15.70M -$0.68 N/A Haemonetics $1.33B 3.68 $97.31M $2.04 52.92

Is AXGN or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to AxoGen's net margin of -13.36%. Haemonetics' return on equity of 27.55% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Haemonetics 7.12% 27.55% 9.65%

Does the media refer more to AXGN or HAE?

In the previous week, Haemonetics had 4 more articles in the media than AxoGen. MarketBeat recorded 6 mentions for Haemonetics and 2 mentions for AxoGen. Haemonetics' average media sentiment score of 0.41 beat AxoGen's score of 0.39 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Haemonetics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, LIVN or AXGN?

AxoGen has lower revenue, but higher earnings than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.47B 2.91 -$242.47M $3.38 23.01 AxoGen $225.21M 10.81 -$15.70M -$0.68 N/A

Is LIVN or AXGN more profitable?

LivaNova has a net margin of 12.82% compared to AxoGen's net margin of -13.36%. LivaNova's return on equity of 16.35% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% AxoGen -13.36% -8.90% -6.47%

Does the media favor LIVN or AXGN?

In the previous week, LivaNova had 5 more articles in the media than AxoGen. MarketBeat recorded 7 mentions for LivaNova and 2 mentions for AxoGen. LivaNova's average media sentiment score of 0.71 beat AxoGen's score of 0.39 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, AXGN or ITGR?

Integer has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.81 -$15.70M -$0.68 N/A Integer $1.85B 2.32 $102.81M $3.66 34.54

Is AXGN or ITGR more profitable?

Integer has a net margin of 6.97% compared to AxoGen's net margin of -13.36%. Integer's return on equity of 12.79% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Integer 6.97% 12.79% 6.48%

Does the media refer more to AXGN or ITGR?

In the previous week, Integer had 11 more articles in the media than AxoGen. MarketBeat recorded 13 mentions for Integer and 2 mentions for AxoGen. Integer's average media sentiment score of 0.50 beat AxoGen's score of 0.39 indicating that Integer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integer 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

AxoGen (AXGN) Competitors

$45.28 -0.16 (-0.35%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$45.85 +0.57 (+1.26%)

As of 06:00 AM Eastern

Compare

AXGN vs. MMED, TFX, HAE, LIVN, and ITGR

Should you buy AxoGen stock or one of its competitors? AxoGen's main competitors and comparable companies include MiniMed Group (MMED), Teleflex (TFX), Haemonetics (HAE), LivaNova (LIVN), and Integer (ITGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does AxoGen compare to MiniMed Group?

AxoGen (NASDAQ:AXGN) and MiniMed Group (NASDAQ:MMED) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

MiniMed Group has a net margin of 0.00% compared to AxoGen's net margin of -13.36%. MiniMed Group's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
MiniMed Group	N/A	N/A	N/A

AxoGen currently has a consensus price target of $51.56, suggesting a potential upside of 13.86%. MiniMed Group has a consensus price target of $23.77, suggesting a potential upside of 7.89%. Given AxoGen's higher probable upside, research analysts plainly believe AxoGen is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

AxoGen has higher earnings, but lower revenue than MiniMed Group. AxoGen is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.81	-$15.70M	-$0.68	N/A
MiniMed Group	$3.22B	1.92	-$333M	-$0.68	N/A

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 0.0% of MiniMed Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, MiniMed Group had 2 more articles in the media than AxoGen. MarketBeat recorded 4 mentions for MiniMed Group and 2 mentions for AxoGen. MiniMed Group's average media sentiment score of 0.51 beat AxoGen's score of 0.39 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiniMed Group	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiniMed Group beats AxoGen on 8 of the 13 factors compared between the two stocks.

How does AxoGen compare to Teleflex?

AxoGen (NASDAQ:AXGN) and Teleflex (NYSE:TFX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

AxoGen has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Teleflex has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

AxoGen has higher earnings, but lower revenue than Teleflex. AxoGen is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.81	-$15.70M	-$0.68	N/A
Teleflex	$1.99B	2.67	-$905.64M	-$23.29	N/A

In the previous week, Teleflex had 1 more articles in the media than AxoGen. MarketBeat recorded 3 mentions for Teleflex and 2 mentions for AxoGen. Teleflex's average media sentiment score of 1.15 beat AxoGen's score of 0.39 indicating that Teleflex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teleflex	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen presently has a consensus target price of $51.56, suggesting a potential upside of 13.86%. Teleflex has a consensus target price of $152.90, suggesting a potential upside of 21.93%. Given Teleflex's higher possible upside, analysts clearly believe Teleflex is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

80.3% of AxoGen shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 0.7% of Teleflex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AxoGen has a net margin of -13.36% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Teleflex	-39.67%	11.93%	5.44%

Summary

Teleflex beats AxoGen on 9 of the 17 factors compared between the two stocks.

How does AxoGen compare to Haemonetics?

AxoGen (NASDAQ:AXGN) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Haemonetics has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.81	-$15.70M	-$0.68	N/A
Haemonetics	$1.33B	3.68	$97.31M	$2.04	52.92

Haemonetics has a net margin of 7.12% compared to AxoGen's net margin of -13.36%. Haemonetics' return on equity of 27.55% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Haemonetics	7.12%	27.55%	9.65%

AxoGen currently has a consensus price target of $51.56, suggesting a potential upside of 13.86%. Haemonetics has a consensus price target of $99.78, suggesting a potential downside of 7.58%. Given AxoGen's stronger consensus rating and higher possible upside, equities analysts plainly believe AxoGen is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

80.3% of AxoGen shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 2.1% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AxoGen has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

In the previous week, Haemonetics had 4 more articles in the media than AxoGen. MarketBeat recorded 6 mentions for Haemonetics and 2 mentions for AxoGen. Haemonetics' average media sentiment score of 0.41 beat AxoGen's score of 0.39 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Haemonetics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Haemonetics beats AxoGen on 11 of the 17 factors compared between the two stocks.

How does AxoGen compare to LivaNova?

LivaNova (NASDAQ:LIVN) and AxoGen (NASDAQ:AXGN) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, LivaNova had 5 more articles in the media than AxoGen. MarketBeat recorded 7 mentions for LivaNova and 2 mentions for AxoGen. LivaNova's average media sentiment score of 0.71 beat AxoGen's score of 0.39 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 2.4% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LivaNova has a net margin of 12.82% compared to AxoGen's net margin of -13.36%. LivaNova's return on equity of 16.35% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
AxoGen	-13.36%	-8.90%	-6.47%

LivaNova currently has a consensus target price of $84.13, suggesting a potential upside of 8.14%. AxoGen has a consensus target price of $51.56, suggesting a potential upside of 13.86%. Given AxoGen's stronger consensus rating and higher probable upside, analysts plainly believe AxoGen is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

LivaNova has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

AxoGen has lower revenue, but higher earnings than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.47B	2.91	-$242.47M	$3.38	23.01
AxoGen	$225.21M	10.81	-$15.70M	-$0.68	N/A

Summary

LivaNova beats AxoGen on 9 of the 16 factors compared between the two stocks.

How does AxoGen compare to Integer?

AxoGen (NASDAQ:AXGN) and Integer (NYSE:ITGR) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

AxoGen currently has a consensus price target of $51.56, suggesting a potential upside of 13.86%. Integer has a consensus price target of $109.86, suggesting a potential downside of 13.09%. Given AxoGen's stronger consensus rating and higher probable upside, equities research analysts clearly believe AxoGen is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Integer has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.81	-$15.70M	-$0.68	N/A
Integer	$1.85B	2.32	$102.81M	$3.66	34.54

In the previous week, Integer had 11 more articles in the media than AxoGen. MarketBeat recorded 13 mentions for Integer and 2 mentions for AxoGen. Integer's average media sentiment score of 0.50 beat AxoGen's score of 0.39 indicating that Integer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integer	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AxoGen has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Integer has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Integer has a net margin of 6.97% compared to AxoGen's net margin of -13.36%. Integer's return on equity of 12.79% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Integer	6.97%	12.79%	6.48%

Summary

Integer beats AxoGen on 10 of the 16 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXGN vs. The Competition

Export

Metric	AxoGen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.44B	$5.52B	$7.20B	$13.72B
Dividend Yield	N/A	1.79%	2.57%	12.64%
P/E Ratio	-66.59	25.20	273.33	25.54
Price / Sales	10.81	69.81	673.52	91.96
Price / Cash	N/A	32.74	77.01	51.20
Price / Book	16.23	5.76	10.46	6.31
Net Income	-$15.70M	$151.55M	$3.48B	$357.99M
7 Day Performance	7.40%	0.87%	0.78%	0.91%
1 Month Performance	-9.78%	-3.11%	-0.30%	-2.57%
1 Year Performance	162.34%	13.26%	18.70%	5.07%

AxoGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXGN AxoGen	2.0725 of 5 stars	$45.28 -0.4%	$51.56 +13.9%	+169.2%	$2.44B	$225.21M	N/A	622
MMED MiniMed Group	1.4995 of 5 stars	$21.83 -0.6%	$23.77 +8.9%	N/A	$6.15B	$3.22B	N/A	2,800	Positive News Gap Down
TFX Teleflex	4.7581 of 5 stars	$127.04 -2.5%	$152.90 +20.4%	-0.3%	$5.41B	$2.25B	N/A	15,500
HAE Haemonetics	1.9275 of 5 stars	$105.10 -1.1%	$99.78 -5.1%	+116.3%	$4.78B	$1.35B	51.52	3,009	Gap Up
LIVN LivaNova	2.7016 of 5 stars	$79.66 -1.2%	$84.13 +5.6%	+42.7%	$4.39B	$1.39B	23.57	3,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXGN) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Competitors

AXGN vs. MMED, TFX, HAE, LIVN, and ITGR

How does AxoGen compare to MiniMed Group?

Summary

How does AxoGen compare to Teleflex?

Summary

How does AxoGen compare to Haemonetics?

Summary

How does AxoGen compare to LivaNova?

Summary

How does AxoGen compare to Integer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXGN vs. The Competition

AxoGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AxoGen (AXGN) Competitors

AXGN vs. MMED, TFX, HAE, LIVN, and ITGR

How does AxoGen compare to MiniMed Group?

Is AXGN or MMED more profitable?

Do analysts prefer AXGN or MMED?

Which has higher earnings & valuation, AXGN or MMED?

Do institutionals & insiders hold more shares of AXGN or MMED?

Does the media prefer AXGN or MMED?

Summary

How does AxoGen compare to Teleflex?

Which has more volatility & risk, AXGN or TFX?

Which has preferable valuation & earnings, AXGN or TFX?

Does the media refer more to AXGN or TFX?

Do analysts prefer AXGN or TFX?

Do institutionals and insiders believe in AXGN or TFX?

Is AXGN or TFX more profitable?

Summary

How does AxoGen compare to Haemonetics?

Which has stronger valuation and earnings, AXGN or HAE?

Is AXGN or HAE more profitable?

Do analysts prefer AXGN or HAE?

Do insiders and institutionals believe in AXGN or HAE?

Which has more volatility and risk, AXGN or HAE?

Does the media refer more to AXGN or HAE?

Summary

How does AxoGen compare to LivaNova?

Does the media favor LIVN or AXGN?

Do insiders & institutionals hold more shares of LIVN or AXGN?

Is LIVN or AXGN more profitable?

Do analysts prefer LIVN or AXGN?

Which has more risk & volatility, LIVN or AXGN?

Which has stronger valuation and earnings, LIVN or AXGN?

Summary

How does AxoGen compare to Integer?

Do analysts recommend AXGN or ITGR?

Which has higher earnings and valuation, AXGN or ITGR?

Does the media refer more to AXGN or ITGR?

Which has more risk & volatility, AXGN or ITGR?

Do insiders and institutionals hold more shares of AXGN or ITGR?

Is AXGN or ITGR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXGN vs. The Competition

AxoGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools